Umbilical Cord Blood Therapy for Cerebral Palsy
- Conditions
- Cerebral Palsy
- Interventions
- Biological: Umbilical Cord Blood InfusionOther: Placebo Umbilical Cord BloodOther: Active Rehabilitation
- Registration Number
- NCT01528436
- Lead Sponsor
- MinYoung Kim, M.D.
- Brief Summary
This randomized controlled study aims to evaluate the efficacy of umbilical cord blood therapy for children with cerebral palsy.
- Detailed Description
Cerebral palsy is a disorder of movement and posture resulted from a non-progressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability.
Many experimental animal studies have revealed that umbilical cord blood is useful to repair neurological injury in brain.
On the basis of many experimental studies, umbilical cord blood is suggested as a potential therapy for cerebral palsy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
- Cerebral Palsy with abnormal muscle tone
- Gross Motor Function Classification System (GMFCS): I, II, III, IV, V
- Willing to comply with all study procedure
- Medical instability including pneumonia or renal function at enrollment
- Presence of known genetic disease
- Presence of drug hypersensitivity which is related to this study remedy
- Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
- Decision by the principal investigator when there are unexpected events including brain surgery, that may affect the outcome
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Umbilical Cord Blood and Rehabilitation Umbilical Cord Blood Infusion Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation Umbilical Cord Blood and Rehabilitation Active Rehabilitation Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation Placebo Umbilical Cord Blood and Rehabilitation Placebo Umbilical Cord Blood Placebo Umbilical Cord Blood infusion and Active Rehabilitation Placebo Umbilical Cord Blood and Rehabilitation Active Rehabilitation Placebo Umbilical Cord Blood infusion and Active Rehabilitation
- Primary Outcome Measures
Name Time Method Changes in Motor Performance Baseline - 1 month - 3 months GMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0\~100, Higher value means better motor quality). We will report GMPM scores at each assessment time points.
Changes in Standardized Gross Motor Function Baseline - 1 month - 3 months GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying \& rolling, sitting, crawling \& kneeling, standing, walking, running \& jumping (range: 0\~100 , Higher value means better gross motor function). We will report GMFM scores at each assessment time points.
- Secondary Outcome Measures
Name Time Method Changes in Cognitive Neurodevelopmental Outcome Baseline - 1 month - 3 months Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scales (higher value means better mental function: 0 - worst, 178 - best). We will report K-BSID-II Mental Scale raw scores at each assessment time points.
Changes in Motor Neurodevelopmental Outcome Baseline - 1 month - 3 months Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scales (higher value means better motor function: 0 - worst, 112 - best). We will report K-BSID-II Motor Scale raw scores at each assessment time points.
Changes in Functional Independence in Daily Activities Baseline - 1 month - 3 months WeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher scores mean more independent performance in daily activities. We will report total WeeFIM scores measured at each assessment time points.
Changes in Visual Perception Test Baseline - 1 month - 3 months We will evaluate visual perception function with one of three measures: DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). All can be scored as percentile rank from 0 to 100. Higher values mean better visual perception ability.
Changes in Muscle Strength Baseline - 1 month - 3 months Summation of MMT (manual muscle strength test score): summated scores of the manual muscle strength test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 \~ 160) Higher scores mean better muscle strength. Categories of outcome table will be summation of MMT scores measured at each assessment time point.
Changes in Functional Performance in Daily Activities Baseline - 1 month - 3 months Pediatric Evaluation of Disability Inventory (PEDI) for assessing functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). We will report 2 scales and 3 domains of each scale: a Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) which are divided respectively into 3 domains: self care, mobility, and social function. Categories of outcome table will be each domain scores measured at each assessment time point.
Changes in Brain Glucose Metabolism Using by Brain 18F-FDG PET Baseline - 2 weeks 18F-FDG PET imaging will be underwent twice prior to and then 2 weeks post-treatment. All scans will be reviewed by a nuclear physician. Spatial pre-processing and statistical analyses will be done using SPM8 implanted in Matlab to compare differences in regional brain glucose metabolism between groups and differences between pre- and post-therapy imaging data. We will reported increased areas and decreased areas of glucose metabolism in two groups.
Trial Locations
- Locations (1)
CHA Bundang Medical Center, CHA University
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of